Bragg Financial Advisors Inc Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Bragg Financial Advisors Inc lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,498 shares of the medical research company’s stock after acquiring an additional 538 shares during the quarter. Bragg Financial Advisors Inc’s holdings in Thermo Fisher Scientific were worth $6,717,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Cypress Advisory Group LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at about $253,000. Mondrian Investment Partners LTD lifted its stake in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock valued at $106,738,000 after buying an additional 127,357 shares in the last quarter. GAMMA Investing LLC lifted its stake in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock valued at $2,419,000 after buying an additional 877 shares in the last quarter. Deutsche Bank AG lifted its stake in Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock valued at $687,553,000 after buying an additional 114,277 shares in the last quarter. Finally, Hancock Whitney Corp lifted its stake in Thermo Fisher Scientific by 0.6% in the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company’s stock valued at $2,802,000 after buying an additional 30 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a research note on Monday. They issued an “outperform” rating on the stock. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Barclays increased their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $593.00.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 295 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total value of $147,511.80. Following the completion of the sale, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,591,606.96. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,896 shares of company stock valued at $8,593,838 in the last quarter. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 2.3%

Shares of NYSE TMO opened at $483.4280 on Friday. The company has a 50 day simple moving average of $441.06 and a 200-day simple moving average of $458.02. The company has a market capitalization of $182.55 billion, a P/E ratio of 27.96, a P/E/G ratio of 2.64 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the firm earned $5.37 EPS. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.